novo nordisk cuts glp-1 drug prices for cash-paying customers. wegovy #ozempic #glp1 #obesity #biotech #pharma #healthcare | David Alderman GoodRx, Novo Nordisk team to
Description
Conclusions According to this multidisciplinary consensus, GLP-1 RAs can be considered easy-to-manage, highly effective medications with a good profile of tolerability to treat people with obesity or T2D
Tirzepatide (Zepbound) was not included as that drug was only approved for obesity late in 2023
Smith, G
10.1038/sj.onc.1203292 [DOI] [PubMed] [Google Scholar] 20.Mattern T, Reich C, Duchrow M, Ansorge S, Ulmer AJ, Flad HD
If confirmed, that mechanism would represent a genuinely novel approach to treating substance use disorders
